GuruFocus Manual of Stocks™  |  Jun 30, 2025
Genmab AS (NAS:GMAB)
www.gurufocus.com/stock/NAS:GMAB/summary
Genmab AS (NAS:GMAB)
[1]
Possible Value Trap, Think Twice[5]$ 20.625
GF Score: 89/100Market Cap: $ 12,721 Mil
Industry: Healthcare - Biotechnology
IPO Date: 2010-10-05
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza... read more
Latest FY Operating Revenue by Business Segment
Business Segment Name2024Percentage
DARZALEX1,94264.68%
Kesimpta310.0110.32%
Net product sales243.188.10%
Milestone revenue139.524.65%
Reimbursement revenue138.964.63%
TEPEZZA102.823.42%
Other Segments126.404.21%
Financial Strength
Rank: 10 /10CurrentIndustry MedianHistorical Median
Cash-to-Debt22.567.749.23
Equity-to-Asset0.800.680.90
Interest Coverage58.68119.89504.14
Piotroski F-Score635
Profitability Rank
Rank: 10 /10CurrentIndustry MedianHistorical Median
Operating Margin %33.34-115.3247.39
Net Margin %35.64-110.2343.53
ROE %22.44-40.44521.33
ROA %18.35-32.4519.32
ROC (Joel Greenblatt) %257.89-311.875225.96
Growth Rank(* per share data)
Rank: 10 /1010-Yr5-Yr1-Yr
Revenue Growth %38.328.718.2
EBITDA Growth %35.619.424.3
Oprt. Income Growth %33.215.323.2
EPS w/o NRI Growth %29.719.632.3
FCF Growth %55.232.939.9
Book Value Growth %32.120.716.5
Momentum Rank
Rank: 5 /10CurrentIndustry MedianHistorical Median
5-Day RSI24.4944.92N/A
9-Day RSI33.0946.45N/A
14-Day RSI40.3347.79N/A
6-1M Momentum %1.24-11.64N/A
12-1M Momentum %-16.81-20.61N/A
Quarterly
Mar24Jun24Sep24Dec24Mar25
Revenue603.00775.47829.79743.78715.00
Net Income192.00202.12189.62495.39195.00
EPS0.290.310.300.770.31
Revenue YoY %45.3527.4724.34-5.4618.57
Net Income YoY %524.593.75-36.37283.001.56
EPS YoY %525.535.41-34.29292.353.74
Free Cash Flow215.00211.49315.83299.45257.00
Cash & Equiv.4,2792,2592,5942,9443,226
Total Current Assets4,9723,1493,5503,8864,037
Short-Term Debt & CLO13.3113.4913.6312.8414.00
Total Current Liabilities399.10626.46686.75740.56756.00
Total Liabilities605.091,0981,1591,2721,290
Stockholders Equity4,7014,4464,7815,1205,296
Warning Signs
SEVEREBeneish M-Score: Possible manipulator
SEVEREOperating Margin %: Declined
SEVEREAsset Growth: Faster than revenue growth
Good Signs
GOODFinancial Strength: Strong Financial Strength
GF Value Rank
Rank: 2 /10CurrentIndustry MedianHistorical Median
PE Ratio12.2529.6949.64
Forward P/E14.3723.15N/A
PB Ratio2.282.5058.34
PS Ratio3.999.1820.26
P/FCF11.3132.1561.80
Shiller P/E23.4434.35119.04
PEG Ratio0.701.9151.06
Valuation Analysis
Current% of Price
NCAV4.6823
Tangible Book5.4326
Graham Number14.2369
Peter Lynch Value16.5380
EPV17.9887
Price20.625
GF Value41.55201
DCF (Earnings Based)58.00281
DCF (FCF Based)64.20311
Median PS Value112.81547
Dividend & Ownership
Dividend Yield (TTM) %N/A
Dividend Yield (Forward) %N/A
Dividend Payout RatioN/A
Dividend Growth (5Y) %N/A
Yield on Cost (5Y) %N/A
Continuous Div. sinceN/A
Insider Ownership %N/A
Institution Ownership %10.40
As of 06-30-2025
* All financial numbers are in millions except for per share data, ratios and percentage change. "Neg. E" means negative equity.
20152016201720182019202020212022202320242025Performance
%GainSP500
1W-0.272.94
1M-1.555.13
3M5.3410.77
6M-1.176.04
YTD-1.176.04
1Y-17.9314.93
3Y-14.0419.53
5Y-9.4516.55
10Y9.0513.53
48.72
21.47
5.78
2M
0.8M
2015201620172018201920202021202220232024CurrentKey Data
13.9419.3723.4821.6824.1440.7648.7247.0643.2232.7728.56Highest Stock Price
5.789.7016.2912.1214.5317.1530.9226.8327.9420.0217.24Lowest Stock Price
7,9779,98910,12810,10614,49526,59725,99827,70420,80113,26112,721Market Cap
607.7617.7620.9620.5636.4658.9660.5660.1659.1646.3639.3Shares Outstanding-Diluted
72.7761.1657.1444.7843.1933.7458.6435.2332.1712.3812.25PE Ratio
15.6214.6210.028.236.888.427.697.064.432.592.28PB Ratio
49.0239.9826.6621.8017.4315.8820.6013.248.504.513.99PS Ratio
64.5057.1149.8334.7428.1623.2736.7622.9318.567.777.19EV-to-EBITDA
2015201620172018201920202021202220232024TTMPer Share Data
0.270.420.610.751.262.541.943.163.714.654.77Revenue per Share
0.180.270.290.360.511.190.681.190.981.691.68Earnings per Share
0.040.070.390.130.291.540.460.781.581.611.69Free Cash Flow per Share
----------------------Dividends per Share
0.811.091.621.893.144.755.085.987.164.795.03Tangible Book per Share
------13.9127.2259.0943.6778.1589.70102.09112.81Median PS Value
1.842.553.583.705.8911.837.9012.2813.2212.5313.14Graham Number
2015201620172018201920202021202220232024TTMIncome Statement
165.97256.98381.12463.40804.481,6711,2812,0882,4463,0033,064Revenue
165.97256.98381.12463.40804.481,6711,2812,0882,4122,8662,914Gross Profit
----------------98.6395.4295.09Gross Margin %
58.98108.01164.53252.00408.99627.75831.821,1861,6221,8891,891Total Operating Expense
106.99148.98216.59211.40395.491,043449.55902.00790.02977.041,022Operating Income
64.4657.9756.8345.6249.1662.4435.0843.2132.3032.5333.37Operating Margin %
111.84167.97177.91225.50324.73786.43450.16784.70646.151,0941,082Net Income
67.3965.3646.6848.6640.3747.0635.1337.5926.4236.4435.32Net Margin %
110.98159.96171.79246.94429.68977.50598.441,005847.331,2951,270EBIT
115.64165.75183.07260.42450.521,020636.191,057891.131,3531,330EBITDA
26.5428.1421.0120.1519.4829.8713.7721.4814.9922.3022.23ROE %
21.5125.5919.7119.1118.2127.2812.4319.4113.5018.8218.18ROA %
2015201620172018201920202021202220232024Mar25Balance Sheet
511.69554.96873.87935.381,6452,6582,9443,2134,1772,9443,226Cash & Equivalents & MS
537.27693.02976.481,1392,0933,1063,4614,0614,9203,8864,037Total Current Assets
571.65741.211,0641,2962,2703,4953,7494,3355,2396,3916,586Total Assets
0.02------3.906.949.4410.6513.3612.8414.00Short-Term Debt & CLO
60.7058.2352.7268.02140.63207.10238.71262.38368.80740.56756.00Total Current Liabilities
--------23.2445.7855.2675.28100.96130.73129.00Long-Term Debt & CLO
60.9158.2353.3068.48164.31334.21370.09408.33546.231,2721,290Total Liabilities
510.74682.981,0111,2282,1063,1603,3793,9274,6935,1205,296Total Stockholders Equity
510.74682.981,0111,2282,1063,1603,3793,9274,6935,1205,296Total Equity
2015201620172018201920202021202220232024TTMCashflow Statement
45.6246.37256.07155.49198.801,063339.18563.051,0961,0841,152Cash Flow from Operations
-70.44-143.56-107.65-272.37-297.30-388.59-146.30-397.39-190.34-1,382-1,215Cash Flow from Investing
94.2012.9034.65-10.88548.7111.74-63.94-113.56-89.97-546.77-474.77Cash Flow from Financing
75.42-80.23167.76-124.85452.61612.88258.35134.72738.50-698.84-382.84Net Change in Cash
128.0243.44217.2381.65532.521,2001,3641,4242,2071,3751,619Ending Cash Position
-19.83-4.69-14.34-73.23-16.64-50.74-38.36-45.63-55.83-42.41-68.41Capital Expenditure
25.7941.69241.7382.26182.161,013300.82517.421,0401,0421,084Free Cash Flow
Competitor(* Up to 5 competitors are listed here. See full competitors list in the Competitive Comparison section below)
TickerCompanyMarket Cap
($M)
PE RatioGF Score
/100
Financial
Strength /10
Profitability
Rank /10
GF Value
Rank /10
Growth
Rank /10
Momentum
Rank /10
HKSE:01801Innovent Biologics Inc16,361At Loss79735106
NAS:SMMTSummit Therapeutics Inc15,596At Loss3281002
NAS:RPRXRoyalty Pharma PLC15,21115.418157669
NAS:GMABGenmab AS12,72112.258910102105
OCSE:ALK BAlk-Abello AS6,47643.2989975910
GuruFocus Manual of Stocks™  |  Jun 30, 2025
Genmab AS (NAS:GMAB)
www.gurufocus.com/stock/NAS:GMAB/summary

Financial Strength[2] (Quarterly data, as of Mar. 2025) : Good (10/10)


Cash-to-Debt : 22.56

Cash-to-Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. A high ratio indicates that a company is better able to pay back its debt, and is thus able to take on more debt if necessary.


Equity-to-Asset : 0.80

Equity-to-Asset ratio is calculated as total stockholders equity divided by its total assets. Equity-to-Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity-to-Asset ratio (more leveraged) may have higher ROE % because of the leverage.


Debt-to-Equity : 0.03

A high Debt-to-Equity ratio generally means that a company has been aggressive in financing its growth with debt.


Piotroski F-Score : 6

The Piotroski F-Score is used to determine the strength of a firm's financial position, with 9 being the best and 0 being the worst.

0
1
2
3
4
5
6
7
8
9


WACC : 6.03% vs ROIC : 39.02%

The weighted average cost of capital (WACC) is the rate that a company is expected to pay on average to all its security holders to finance its assets. Return on invested capital (ROIC) measures how well a company generates cash flow relative to the capital it has invested in its business.


Dividend Yield : 0.00%

Dividend yield is a way to measure how much cash flow you are getting for each dollar invested in an equity position.

GuruFocus Manual of Stocks™  |  Jun 30, 2025
Genmab AS (NAS:GMAB)
www.gurufocus.com/stock/NAS:GMAB/summary

Profitability[3] (Annual data, as of Dec. 2024) : Good (10/10)


Revenue : $715 Mil vs Net Income : $195 Mil

Revenue is the amount of money that a company actually receives during a specific period, including discounts and deductions for returned merchandise. Net Income is a company's total profit. Net income is calculated by taking revenues and adjusting for the cost of doing business, depreciation, interest, taxes and other expenses.


Cash & Equivalents : $1,619 Mil vs Long-Term Debt* : $129 Mil

Cash & equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash. Long-Term Debt* consists of loans and obligations lasting over one year.


Operating Margin % : 26.29%

Operating margin % measures how much profit a company makes on a dollar of sales. Operating Margin % is calculated as Operating Income divided by Revenue.


EPS without NRI : $0.27

Earnings Per Share without Non-Recurring Items is the amount of earnings without non-recurring items per outstanding share of the company's stock. In calculating earnings per share without non-recurring items, the dividends of preferred stocks and Non Operating Income need to subtracted from the total net income first.


Dividends per Share : $0.00

Dividends per Share is the amount of dividends that the shareholders of a company receive on a per-share basis. It is calculated using the total dividends paid out to shareholders over one fiscal year and the number of shares outstanding.


Free Cash Flow per Share : $0.40

Free Cash flow per Share is the amount of Free cash flow per outstanding share of the company's stock.

GuruFocus Manual of Stocks™  |  Jun 30, 2025
Genmab AS (NAS:GMAB)
www.gurufocus.com/stock/NAS:GMAB/summary

Valuation (Quarterly data, as of Mar. 2025)

These valuation metrics should give you a sense of reasonable prices, but be careful with them. Always seek to understand why a valuation is changing over time.


Valuation Chart (Current stock price : $20.625)


PE Ratio without NRI : 12.66

The price-to-earnings ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than regular PE Ratio.


PB Ratio : 2.34

The price-to-book ratio measures the valuation of the stock relative to the underlying asset of the company.


PS Ratio : 4.06

The price-to-sales ratio is a valuation ratio that compares a company’s stock price to its revenues. The price-to-sales ratio is an indicator of the value placed on each dollar of a company’s sales or revenues.


Price-to-Free-Cash-Flow : 11.47

Price-to-free-cash-flow is very similar to the valuation metric of price-to-operating-cash-flow but is considered a more exact measure, owing to the fact that it uses free cash flow, which subtracts capital expenditures from a company's total operating cash flow, thereby reflecting the actual cash flow available to fund non-asset-related growth.


EV-to-EBIT : 7.21

Enterprise value of a company divided by its trailing 12 months earnings before interest and taxes (EBIT).

GuruFocus Manual of Stocks™  |  Jun 30, 2025
Genmab AS (NAS:GMAB)
www.gurufocus.com/stock/NAS:GMAB/summary

Valuation Bands

In these charts the 10-year valuation bands of the price-to-earnings ratio (PE Ratio), price-to-book ratio (PB Ratio), price-to-sales ratio (PS Ratio) and price-to-operating-cash-flow ratio (POCF) are drawn together with the historical stock prices. For example, the upper line of the PE band is where the stock price would have been if it were always traded at the maximum PE ratio of the past 10 years. The lower line of the PE band is where the stock price would have been if it were always traded at the lowest PE ratio of the past 10 years. It is always better if the stock price is close to the lower line, which indicates a lower valuation.


Historical Price and PE Band


Historical Price and PS Band


Historical Price and PB Band


Historical Price and Price-to-Operating-Cash-Flow (POCF) Band

GuruFocus Manual of Stocks™  |  Jun 30, 2025
Genmab AS (NAS:GMAB)
www.gurufocus.com/stock/NAS:GMAB/summary

Warning Signs

GuruFocus conducted a thorough checkup using a checklist of 32 items that cover the areas of financial strength, profitability, growth, and valuation of each company. The purpose of Warning Signs is to warn you that the company may have red flags in certain areas, helping to avoid overlooking them. These warning signs do not necessarily mean you should not invest in the stock. But you should be aware of them before you invest.


Severe Warning Signs

Beneish M-Score : Possible manipulator

Beneish M-Score 8.34 higher than -1.78, which implies that the company might have manipulated its financial results.

Operating Margin % : Declined

Genmab AS operating margin has been in a 5-year decline. The average rate of decline per year is -10.4%.

Asset Growth : Faster than revenue growth

If a company builds assets at 34.1% a year, faster than its revenue growth rate of 28.7% over the past 5 years, it means that the company may be getting less efficient.

Good Signs

Financial Strength : Strong Financial Strength

Genmab AS shows strong financial strength.

Altman Z-Score : Strong

Altman Z-score of 7.9 is strong.

Interest Coverage : Comfortable

Ben Graham prefers companies' interest coverage to be at least 5. Genmab AS has enough cash to cover all of its debt. Its financial situation is stable.

Medium Warning Signs

Valuation : Forward PE Ratio

Company's forward PE ratio is higher than the trailing PE ratio. Company's earnings are in decline.
GuruFocus Manual of Stocks™  |  Jun 30, 2025
Genmab AS (NAS:GMAB)
www.gurufocus.com/stock/NAS:GMAB/summary

Competitive Comparison


5 Year Price Change Comparison



Financial Strength

CompanyFinancial StrengthCash-to-DebtEquity-to-AssetDebt-to-EquityInterest CoveragePiotroski F-ScoreAltman Z-ScoreBeneish M-ScoreWACC %ROIC %
OCSE:BAVABavarian Nordic AS10/1010.570.850.0121.3556.13-1.538.6511.87
NAS:GMABGenmab AS10/1022.560.800.0358.6867.908.346.0339.02
XBRU:ARGXargenx SE10/1086.520.890.0170.37327.16-0.240.1641.43
OCSE:ALK BAlk-Abello AS9/100.650.690.1449.76712.20-2.576.0415.97
NAS:REGNRegeneron Pharmaceuticals Inc9/103.090.780.0980.1556.61-2.295.3514.36
NAS:BNTXBioNTech SE8/1048.160.890.020.0038.36-2.848.78-10.81
XKRX:207940Samsung BioLogics Co Ltd8/100.910.650.1336.1388.06-2.514.538.66
NAS:SMMTSummit Therapeutics Inc8/1056.020.900.020.0030.000.00-11.01-506.07
NAS:VRTXVertex Pharmaceuticals Inc8/103.760.720.100.00212.05-2.356.32-11.10
NAS:ONCBeOne Medicines Ltd7/102.520.600.29N/A66.08-2.523.49-14.36
XKRX:068270Celltrion Inc7/100.440.820.138.5466.57-2.364.272.24
OCSE:GUBRAGubra AS7/104.380.740.210.00533.81-3.088.30-24.72
HKSE:01801Innovent Biologics Inc7/102.790.610.223.7668.12-2.138.652.47
OCSE:STRAPStrategic Partners A/S7/10No Debt0.820.000.0030.000.000.63-5.66
XBRU:UCBUCB SA7/100.580.580.306.1793.94-2.385.486.03
OCSE:PEGPharma Equity Group AS6/100.140.750.230.0030.000.006.56-30.48
OCSE:ZEALZealand Pharma AS6/1021.650.910.050.00418.5811.198.62-151.07
NAS:ALNYAlnylam Pharmaceuticals Inc5/102.020.0311.280.0054.74-1.905.39-7.75
ASX:CSLCSL Ltd5/100.140.460.706.5763.92-2.177.606.80
NAS:INSMInsmed Inc4/101.050.0611.530.0042.36-2.779.52-148.44
GuruFocus Manual of Stocks™  |  Jun 30, 2025
Genmab AS (NAS:GMAB)
www.gurufocus.com/stock/NAS:GMAB/summary

Competitive Comparison - Cont.


Profitability

CompanyProfitability RankOperating
Margin %
Net Margin %ROE %ROA %Price-to-Free-Cash-FlowROC (Joel Greenblatt) %3-Year Revenue Growth %3-Year EBITDA Growth %3-Year EPS w/o NRI Growth %
ASX:CSLCSL Ltd10/1018.7917.9615.757.1151.2726.7215.7012.206.40
XKRX:068270Celltrion Inc10/1017.0913.902.992.4850.3218.2611.60-6.30-18.40
NAS:GMABGenmab AS10/1033.3435.6422.4418.3511.31257.8937.4033.0042.40
NAS:REGNRegeneron Pharmaceuticals Inc9/1027.2031.9415.7012.2820.1950.28-4.90-18.80-15.10
XKRX:207940Samsung BioLogics Co Ltd9/1032.3726.1212.047.65511.3830.9539.7037.0038.60
XBRU:UCBUCB SA8/1014.0417.3111.436.5935.9579.102.107.10-13.50
NAS:VRTXVertex Pharmaceuticals Inc8/10-3.77-8.91-6.04-4.430.00-12.5713.60-44.80-68.20
OCSE:ALK BAlk-Abello AS7/1021.7916.4218.2012.522470.6733.6112.1036.7054.90
OCSE:BAVABavarian Nordic AS6/1021.3021.2012.179.460.0046.9734.50150.600.00
NAS:BNTXBioNTech SE4/10-23.54-27.92-3.97-3.460.00-57.26-47.400.000.00
XBRU:ARGXargenx SE4/108.4041.9523.2620.740.0059.2955.000.000.00
NAS:ALNYAlnylam Pharmaceuticals Inc3/10-4.91-11.490.00-6.580.00-29.7835.2035.5042.30
NAS:ONCBeOne Medicines Ltd3/10-7.08-9.40-11.54-6.770.00-17.1341.9036.9027.00
HKSE:01801Innovent Biologics Inc3/102.70-1.04-0.76-0.460.00-0.2719.800.0061.00
OCSE:GUBRAGubra AS2/10-18.82-13.73-7.85-5.920.00-39.811.400.000.00
NAS:INSMInsmed Inc2/10-225.44-265.93-1146.32-57.250.00-833.279.70-13.40-13.40
OCSE:PEGPharma Equity Group AS2/100.000.00-80.86-33.160.00-5475.550.000.000.00
NAS:SMMTSummit Therapeutics Inc1/100.000.00-85.36-65.390.00-2858.420.0023.1022.00
OCSE:ZEALZealand Pharma AS1/10-2550.13-2128.64-15.58-14.110.00-315.04-28.002.501.30
OCSE:STRAPStrategic Partners A/S0/100.000.00-1.78-1.390.000.000.0093.7093.60

Valuation

CompanyPE RatioPB RatioPS RatioPrice-to-Intrinsic-Value-Projected-FCFPrice-to-Intrinsic-Value-DCF (Earnings Based)Price-to-Median-PS-ValuePrice-to-Peter-Lynch-Fair-ValuePrice-to-Graham-NumberEarnings Yield (Joel Greenblatt) %Forward Rate of Return (Yacktman) %
NAS:ALNYAlnylam Pharmaceuticals IncAt Loss366.7317.910.000.000.310.000.00-0.520.00
NAS:ONCBeOne Medicines LtdAt Loss7.486.230.000.000.000.000.00-1.120.00
NAS:BNTXBioNTech SEAt Loss1.268.670.440.000.000.000.00-7.530.00
OCSE:GUBRAGubra ASAt Loss19.0432.160.000.000.000.000.00-0.430.00
HKSE:01801Innovent Biologics IncAt Loss9.1712.640.000.000.000.000.00-0.010.00
NAS:INSMInsmed IncAt Loss183.4745.490.000.000.000.000.00-4.930.00
OCSE:PEGPharma Equity Group ASAt Loss3.260.000.000.000.000.000.00-12.530.00
OCSE:STRAPStrategic Partners A/SAt Loss2.200.000.000.000.000.000.00-0.920.00
NAS:SMMTSummit Therapeutics IncAt Loss45.650.000.000.000.000.000.00-1.580.00
NAS:VRTXVertex Pharmaceuticals IncAt Loss6.9310.352.500.000.800.000.00-0.25-10.86
OCSE:ZEALZealand Pharma ASAt Loss3.06423.790.000.000.000.000.00-6.370.00
OCSE:BAVABavarian Nordic AS10.141.142.160.000.000.320.001.0611.420.00
NAS:GMABGenmab AS12.252.283.990.850.360.181.251.4513.2616.27
NAS:REGNRegeneron Pharmaceuticals Inc13.361.934.240.770.400.570.001.059.9410.01
ASX:CSLCSL Ltd29.354.425.272.651.780.623.369.934.2910.24
XBRU:UCBUCB SA31.063.235.382.190.002.800.0012.243.93-2.88
XBRU:ARGXargenx SE31.065.5512.940.000.000.340.003.141.280.00
OCSE:ALK BAlk-Abello AS43.297.237.116.270.001.381.734.503.0920.40
XKRX:207940Samsung BioLogics Co Ltd55.186.2514.416.550.000.002.145.392.3620.24
XKRX:068270Celltrion Inc67.172.079.082.102.690.480.005.452.201.21
GuruFocus Manual of Stocks™  |  Jun 30, 2025
Genmab AS (NAS:GMAB)
www.gurufocus.com/stock/NAS:GMAB/summary

Peter Lynch Chart[4]

GuruFocus Manual of Stocks™  |  Jun 30, 2025
Genmab AS (NAS:GMAB)
www.gurufocus.com/stock/NAS:GMAB/summary

Per Share Data


Per Share Data

Dec09
Dec10
Dec11
Dec12
Dec13
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
Dec23
Dec24
TTM Fiscal Period
0.25
0.23
0.14
0.19
0.24
0.24
0.27
0.42
0.61
0.75
1.26
2.54
1.94
3.16
3.71
4.65
4.77
Revenue per Share
-0.03
-0.03
-0.08
-0.04
0.03
0.09
0.19
0.27
0.30
0.42
0.71
1.55
0.96
1.60
1.35
2.09
2.07
EBITDA per Share
-0.07
-0.03
-0.08
-0.04
0.03
0.09
0.18
0.26
0.28
0.40
0.68
1.48
0.91
1.52
1.29
2.00
1.98
EBIT per Share
-0.43
-0.13
-0.23
-0.19
0.04
0.09
0.18
0.27
0.29
0.36
0.51
1.19
0.68
1.19
0.98
1.69
1.68
Earnings per Share (Diluted)
-0.15
-0.06
-0.09
-0.04
0.03
0.09
0.19
0.26
0.35
0.32
0.49
1.31
0.55
1.12
1.08
1.46
1.53
EPS without NRI
--
--
--
-0.12
-0.05
0.02
0.04
0.06
0.36
0.17
0.18
1.43
0.45
0.80
1.28
1.52
1.73
Owner Earnings per Share (TTM)
-0.25
0.10
-0.17
0.02
-0.05
0.02
0.04
0.07
0.39
0.13
0.29
1.54
0.46
0.78
1.58
1.61
1.69
Free Cash Flow per Share
-0.24
0.11
-0.17
0.03
-0.05
0.04
0.08
0.08
0.41
0.25
0.31
1.61
0.51
0.85
1.66
1.68
1.80
Operating Cash Flow per Share
0.55
0.66
0.43
0.53
0.56
0.76
0.86
0.92
1.43
1.53
2.53
4.06
4.48
4.92
6.39
4.63
5.09
Cash per Share
0.56
0.43
0.19
0.14
0.24
0.58
0.86
1.13
1.66
2.00
3.25
4.83
5.14
6.01
7.18
8.06
8.36
Book Value per Share
0.56
0.43
0.19
0.14
0.24
0.57
0.81
1.09
1.62
1.89
3.14
4.75
5.08
5.98
7.16
4.79
5.03
Tangible Book per Share
0.01
0.05
0.01
0.00
0.00
--
--
--
--
--
0.04
0.08
0.10
0.13
0.18
0.23
0.23
Total Debt per Share
--
1.35
0.65
1.40
3.91
5.86
13.40
16.58
16.58
16.48
22.33
40.66
39.56
42.38
31.84
20.87
20.63
Month End Stock Price
449
449
449
460
519
573
608
618
621
620
636
659
660
660
659
646
639
Shares Outstanding (Diluted Average)

Ratios

Dec09
Dec10
Dec11
Dec12
Dec13
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
Dec23
Dec24
TTM Fiscal Period
-59.07
-25.92
-75.00
-113
21.89
21.67
26.54
28.14
21.01
20.15
19.48
29.87
13.77
21.48
14.99
22.30
22.23
ROE %
--
-8.23
-21.80
-10.90
1.32
2.16
1.70
1.92
2.10
2.45
2.83
3.55
1.79
3.04
3.38
8.61
9.84
ROE % Adjusted to Book Value
-37.54
-13.18
-29.08
-30.13
6.70
12.48
21.51
25.59
19.71
19.11
18.21
27.28
12.43
19.41
13.50
18.82
18.18
ROA %
-64.85
-25.92
-75.00
-113
21.95
22.19
27.81
29.47
21.59
21.01
20.35
30.60
13.97
21.66
15.06
28.34
33.85
Return-on-Tangible-Equity
-39.79
-13.18
-29.08
-30.13
6.71
12.65
22.34
26.69
20.22
19.88
18.97
27.89
12.59
19.56
13.55
22.94
25.27
Return-on-Tangible-Asset
-31.88
-156
-556
-385
289
1,173
2,638
361
240
226
161
278
157
169
122
237
256
ROC (Joel Greenblatt) %
-9.30
-6.41
-23.48
-20.47
10.48
19.17
25.46
26.80
20.28
22.05
25.59
36.09
17.61
26.51
18.95
24.62
23.90
ROCE %
--
--
--
--
-49.78
-50.12
-372
117
28.11
23.28
20.12
34.15
13.40
21.82
10.55
9.02
5.46
5-Year RORE %
--
73.73
15.96
56.36
-66.36
-81.00
-444
57.49
-224
-11.63
54.68
434
1,335
135
85.13
8.35
9.93
1-Year ROIIC %
-32.49
-15.98
-22.19
-11.08
7.60
33.08
117
130
139
84.94
76.67
146
54.58
97.34
76.88
48.70
38.92
ROIC %
17.63
9.67
7.22
5.57
5.98
3.15
7.07
7.95
8.15
4.79
4.95
8.32
9.63
10.55
9.25
2.77
6.03
WACC %
924
49.36
2.74
31.40
84.21
256
45.33
176
--
--
3.87
4.14
3.37
7.45
10.38
12.98
11.89
Effective Interest Rate on Debt %
--
-0.08
-51.74
--
--
--
--
--
--
--
--
--
--
--
98.63
95.42
95.09
Gross Margin %
-84.98
-27.61
-71.07
-24.08
10.44
31.18
64.46
57.97
56.83
45.62
49.16
62.44
35.08
43.21
32.30
32.53
33.37
Operating Margin %
-172
-55.23
-170
-101
16.93
35.43
67.39
65.36
46.68
48.66
40.37
47.06
35.13
37.59
26.42
36.44
35.32
Net Margin %
-13.16
-10.61
-54.92
-19.86
12.12
36.89
69.68
64.50
48.03
56.20
56.00
61.05
49.65
50.64
36.43
45.05
43.41
EBITDA Margin %
-100
44.33
-127
12.78
-20.85
6.73
15.54
16.22
63.42
17.75
22.64
60.59
23.48
24.78
42.52
34.69
35.37
FCF Margin %
0.02
0.12
0.02
0.02
0.00
--
--
--
--
--
0.01
0.02
0.02
0.02
0.02
0.03
0.03
Debt-to-Equity
0.58
0.44
0.31
0.23
0.38
0.71
0.89
0.92
0.95
0.95
0.93
0.90
0.90
0.91
0.90
0.80
0.80
Equity-to-Asset
0.01
0.05
0.01
0.00
0.00
--
--
--
--
--
0.01
0.02
0.02
0.02
0.02
0.02
0.02
Debt-to-Asset
0.42
0.57
0.69
0.77
0.62
0.29
0.11
0.08
0.05
0.05
0.07
0.10
0.10
0.09
0.10
0.20
0.20
Liabilities-to-Assets
21.76
-0.02
-8.86
29.98
39.59
35.22
31.93
39.15
42.22
39.27
45.11
57.98
35.38
51.65
50.39
49.28
48.94
Gross-Profit-to-Asset %
--
1.26
0.46
0.54
0.80
0.51
0.79
1.06
-0.20
5.84
0.39
0.86
1.05
1.35
1.07
1.41
1.89
Degree of Financial Leverage
0.22
0.24
0.17
0.30
0.40
0.35
0.32
0.39
0.42
0.39
0.45
0.58
0.35
0.52
0.51
0.52
0.51
Asset Turnover
81.12
55.63
71.81
77.88
73.40
55.80
47.13
116
111
117
148
93.41
131
117
116
101
101
Days Sales Outstanding
--
25.42
22.95
--
--
--
--
--
--
--
--
--
--
--
--
--
-- Days Payable
--
--
--
--
--
--
--
--
--
--
--
--
--
--
92.06
22.73
25.11
Days Inventory
81.12
30.21
48.86
77.88
73.40
55.80
47.13
116
111
117
148
93.41
131
117
208
123
126
Cash Conversion Cycle
4.50
6.56
5.08
4.69
4.97
6.54
7.74
3.14
3.29
3.12
2.47
3.91
2.79
3.13
3.14
3.63
3.63
Receivables Turnover
--
--
--
--
--
--
--
--
--
--
--
--
--
--
3.96
16.06
14.53
Inventory Turnover
--
1.00
1.52
--
--
--
--
--
--
--
--
--
--
--
0.01
0.05
0.05
COGS-to-Revenue
0.06
--
--
--
--
--
--
--
--
--
--
--
--
--
0.00
0.00
0.00
Inventory-to-Revenue
0.03
0.02
0.02
0.02
0.02
0.09
0.12
0.02
0.04
0.16
0.02
0.03
0.03
0.02
0.02
0.01
0.02
Capex-to-Revenue
--
--
--
--
0.15
0.28
0.19
0.03
0.07
0.35
0.04
0.05
0.09
0.05
0.07
0.04
0.07
Capex-to-Operating-Income
--
0.04
--
0.13
--
0.57
0.44
0.10
0.06
0.47
0.08
0.05
0.11
0.08
0.05
0.04
0.06
Capex-to-Operating-Cash-Flow
* All financial numbers are in millions except for per share data, ratios and percentage change. When Return-on-Tangible-Equity displays Neg. E, it means the the tangible equity is negative. When ROE % or ROE % Adjusted to Book Value displays Neg. E, it means the the total shareholders equity is negative.
GuruFocus Manual of Stocks™  |  Jun 30, 2025
Genmab AS (NAS:GMAB)
www.gurufocus.com/stock/NAS:GMAB/summary

Financial Statement

Income Statement

Dec09
Dec10
Dec11
Dec12
Dec13
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
Dec23
Dec24
TTM Fiscal Period
113
104
61.25
85.90
123
139
166
257
381
463
804
1,671
1,281
2,088
2,446
3,003
3,064
Revenue
--
104
92.94
--
--
--
--
--
--
--
--
--
--
--
33.56
137
151
Cost of Goods Sold
113
-0.08
-31.69
85.90
123
139
166
257
381
463
804
1,671
1,281
2,088
2,412
2,866
2,914
Gross Profit
--
-0.08
-51.74
--
--
--
--
--
--
--
--
--
--
--
98.63
95.42
95.09
Gross Margin %
28.64
28.59
11.84
11.45
12.35
12.99
13.36
14.49
23.69
32.78
51.27
109
195
385
490
529
532
Selling, General, & Admin. Expense
180
--
92.94
95.13
97.65
82.56
71.43
93.51
141
219
358
518
636
801
1,133
1,360
1,359
Research & Development
0.00
-0.00
-92.94
-0.00
-0.00
0.00
-25.81
--
-0.00
-0.00
-0.00
-0.00
-0.00
0.00
-0.00
--
0.00
Other Operating Expense
209
28.59
11.84
107
110
95.55
58.98
108
165
252
409
628
832
1,186
1,622
1,889
1,891
Total Operating Expense
-95.90
-28.67
-43.53
-20.68
12.82
43.30
107
149
217
211
395
1,043
450
902
790
977
1,022
Operating Income
-84.98
-27.61
-71.07
-24.08
10.44
31.18
64.46
57.97
56.83
45.62
49.16
62.44
35.08
43.21
32.30
32.53
33.37
Operating Margin %
4.82
0.25
3.88
3.16
5.30
6.26
5.46
4.61
6.61
9.65
17.99
30.41
29.99
46.63
144
139
123
  Interest Income
-34.87
-7.07
-0.36
-0.48
-0.62
-0.66
-0.02
-0.03
-0.32
--
-1.05
-1.65
-1.98
-5.61
-10.39
-16.74
-17.28
  Interest Expense
-30.05
-6.82
3.52
2.68
4.68
5.60
5.44
4.58
6.29
9.65
16.94
28.76
28.01
41.02
134
122
105
Net Interest Income
60.09
13.65
3.39
-2.22
-5.39
-0.34
-1.46
6.37
-51.41
25.89
16.19
-96.36
119
56.56
-86.86
179
125
Other Income (Expense)
-65.85
-21.84
-36.62
-20.22
12.11
48.55
111
160
171
247
429
976
596
1,000
837
1,279
1,252
Pre-Tax Income
-1.14
-3.72
-1.03
0.47
0.88
0.65
0.88
8.05
6.45
-21.45
-104
-189
-146
-215
-191
-184
-170
Tax Provision
-1.73
-17.05
-2.82
2.31
-7.27
-1.33
-0.79
-5.03
-3.76
8.69
24.24
19.41
24.53
21.50
22.80
14.40
13.59
Tax Rate %
-128
-31.78
-66.43
-66.58
7.81
-0.00
-0.00
0.00
--
0.00
--
-0.00
-0.00
--
-0.00
--
-0.00
Other Net Income (Loss)
-195
-57.34
-104
-86.34
20.80
49.19
112
168
178
225
325
786
450
785
646
1,094
1,082
Net Income Including Noncontrolling Interests
-66.99
-25.57
-37.66
-19.75
12.99
49.19
112
168
178
225
325
786
450
785
646
1,094
1,082
  Net Income (Continuing Operations)
-128
-31.78
-66.43
-66.58
7.81
--
--
--
--
--
--
--
--
--
--
--
--   Net Income (Discontinued Operations)
-195
-57.34
-104
-86.34
20.80
49.19
112
168
178
225
325
786
450
785
646
1,094
1,082
Net Income
-172
-55.23
-170
-101
16.93
35.43
67.39
65.36
46.68
48.66
40.37
47.06
35.13
37.59
26.42
36.44
35.32
Net Margin %
-0.43
-0.13
-0.23
-0.19
0.04
0.09
0.19
0.28
0.29
0.37
0.52
1.21
0.69
1.20
0.99
1.71
1.69
EPS (Basic)
-0.43
-0.13
-0.23
-0.19
0.04
0.09
0.18
0.27
0.29
0.36
0.51
1.19
0.68
1.19
0.98
1.69
1.68
EPS (Diluted)
449
449
449
460
519
573
608
618
621
620
636
659
660
660
659
646
639
Shares Outstanding (Diluted Average)
-30.98
-14.77
-36.27
-19.74
12.72
49.21
111
160
172
247
430
977
598
1,005
847
1,295
1,270
EBIT
16.13
3.75
2.63
2.68
2.16
2.01
4.66
5.80
11.28
13.48
20.84
42.81
37.76
52.10
43.80
57.62
60.62
Depreciation, Depletion and Amortization
-14.85
-11.02
-33.64
-17.06
14.88
51.22
116
166
183
260
451
1,020
636
1,057
891
1,353
1,330
EBITDA
-13.16
-10.61
-54.92
-19.86
12.12
36.89
69.68
64.50
48.03
56.20
56.00
61.05
49.65
50.64
36.43
45.05
43.41
EBITDA Margin %
* All financial numbers are in millions except for per share data, ratios and percentage change.
GuruFocus Manual of Stocks™  |  Jun 30, 2025
Genmab AS (NAS:GMAB)
www.gurufocus.com/stock/NAS:GMAB/summary

Financial Statement

Cashflow Statement

Dec09
Dec10
Dec11
Dec12
Dec13
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
Dec23
Dec24
TTM Fiscal Period
-193
-53.62
-103
-86.80
19.92
48.55
111
160
171
247
429
976
596
1,000
837
1,279
1,274
Net Income From Continuing Operations
16.13
3.75
2.63
2.68
2.16
2.01
4.66
5.80
11.28
13.48
20.84
42.81
37.76
52.10
43.80
57.62
60.62
Depreciation, Depletion and Amortization
9.94
--
-0.15
-8.34
-0.17
6.83
-13.18
-112
43.51
-118
-249
50.58
-154
-306
118
-222
-137
  Change In Receivables
13.30
6.30
-0.26
--
--
--
--
--
--
--
--
--
--
--
-8.46
-0.70
3.30
  Change In Inventory
-0.57
-0.22
0.11
--
--
--
--
--
--
--
--
--
--
--
--
--
--   Change In Prepaid Assets
--
--
4.41
3.68
6.38
0.74
-0.69
-1.33
7.57
20.53
65.97
27.77
46.28
40.73
92.35
120
44.57
  Change In Payables And Accrued Expense
-38.33
61.43
-39.54
35.76
-50.67
-43.77
-65.00
-7.72
-12.41
0.00
-0.00
84.79
--
0.00
--
0.00
-0.00
  Change In Other Working Capital
-15.65
67.50
-35.44
31.10
-44.45
-36.21
-78.87
-122
38.68
-97.12
-183
163
-107
-265
202
-103
-88.96
Change In Working Capital
--
--
3.50
2.13
2.14
4.53
5.36
7.53
12.25
13.94
22.04
33.06
47.19
63.19
87.01
101
102
Stock Based Compensation
--
--
59.74
58.65
--
--
--
--
--
--
--
--
--
--
--
16.04
8.04
Asset Impairment Charge
83.23
30.20
-3.69
4.81
-3.46
2.78
3.51
-5.34
22.40
-21.75
-90.10
-152
-235
-287
-74.24
-266
-203
Cash Flow from Others
-110
47.84
-76.31
12.57
-23.69
21.66
45.62
46.37
256
155
199
1,063
339
563
1,096
1,084
1,152
Cash Flow from Operations
-3.23
-1.80
-1.26
-1.60
-1.41
-1.99
-1.38
-1.73
-14.34
-11.03
-11.84
-50.74
-38.36
-45.63
-54.34
-26.09
-34.09
Purchase Of Property, Plant, Equipment
0.07
0.25
0.11
0.11
9.72
0.01
--
--
--
--
--
--
--
--
--
--
-- Sale Of Property, Plant, Equipment
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
-1,709
-- Purchase Of Business
--
--
0.07
--
--
--
--
--
--
--
--
--
--
--
--
--
-- Sale Of Business
-92.96
-283
-190
-315
-180
-437
-304
-426
-552
-539
-871
-2,052
-2,377
-1,396
-1,619
-1,205
-814
Purchase Of Investment
284
153
281
242
185
285
253
287
459
340
591
1,714
2,269
1,044
1,485
1,574
1,376
Sale Of Investment
-3.23
--
--
--
-0.50
-10.33
-18.45
-2.95
--
-62.20
-4.80
--
--
--
-1.49
-16.32
-18.00
Net Intangibles Purchase And Sale
3.23
0.00
--
-0.00
-0.00
0.00
-0.00
0.00
--
-0.00
0.00
0.00
-0.00
--
0.00
-0.00
-1,725
Cash From Other Investing Activities
188
-132
89.84
-73.79
12.39
-165
-70.44
-144
-108
-272
-297
-389
-146
-397
-190
-1,382
-1,215
Cash Flow from Investing
0.32
--
--
64.94
--
163
0.38
0.12
--
--
581
--
--
--
--
--
-- Issuance of Stock
--
--
--
--
--
--
--
-16.71
--
-22.37
--
--
-68.05
-131
-83.74
-541
-462
Repurchase of Stock
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--   Issuance of Debt
--
--
-1.06
-1.10
-0.72
-0.35
-0.04
-0.02
--
--
-4.65
-7.27
-8.83
-10.51
-13.51
-8.37
-7.37
  Payments of Debt
--
--
-1.06
-1.10
-0.72
-0.35
-0.04
-0.02
--
--
-4.65
-7.27
-8.83
-10.51
-13.51
-8.37
-7.37
Net Issuance of Debt
-1.59
-1.25
-1.06
--
--
--
--
--
--
--
--
--
--
--
--
--
-- Cash Flow for Lease Financing
-0.00
--
1.06
-0.42
28.79
6.41
93.86
29.52
--
11.49
-27.29
19.01
12.94
27.64
7.28
2.79
-5.21
Other Financing
-1.28
-1.25
-1.06
63.42
28.07
169
94.20
12.90
34.65
-10.88
549
11.74
-63.94
-114
-89.97
-547
-475
Cash Flow from Financing
13.48
82.85
-0.36
12.30
14.62
27.45
52.60
124
49.47
206
79.91
587
1,105
1,289
1,469
2,074
2,002
Beginning Cash Position
-0.69
1.93
0.01
-0.50
-0.27
5.48
6.04
4.06
-15.31
2.91
2.40
-73.55
129
82.62
-76.91
146
155
  Effect of Exchange Rate Changes
75.95
-83.23
12.48
1.70
16.50
31.18
75.42
-80.23
168
-125
453
613
258
135
739
-699
-383
Net Change in Cash
89.43
-0.37
12.11
14.00
31.12
58.63
128
43.44
217
81.65
533
1,200
1,364
1,424
2,207
1,375
1,619
Ending Cash Position
-3.23
-1.80
-1.26
-1.60
-1.92
-12.32
-19.83
-4.69
-14.34
-73.23
-16.64
-50.74
-38.36
-45.63
-55.83
-42.41
-68.41
Capital Expenditure
-113
46.04
-77.57
10.98
-25.61
9.34
25.79
41.69
242
82.26
182
1,013
301
517
1,040
1,042
1,084
Free Cash Flow
* All financial numbers are in millions except for per share data, ratios and percentage change.
GuruFocus Manual of Stocks™  |  Jun 30, 2025
Genmab AS (NAS:GMAB)
www.gurufocus.com/stock/NAS:GMAB/summary

Financial Satement

Balance Sheet

Dec09
Dec10
Dec11
Dec12
Dec13
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
Dec23
Dec24
TTM Fiscal Period
88.71
18.01
11.38
11.87
31.12
58.63
128
43.44
217
81.65
533
1,200
1,364
1,424
2,207
1,375
1,619
  Cash And Cash Equivalents
157
276
181
255
257
376
384
512
657
854
1,112
1,458
1,580
1,789
1,970
1,569
1,607
  Marketable Securities
246
294
192
267
288
434
512
555
874
935
1,645
2,658
2,944
3,213
4,177
2,944
3,226
Cash, Cash Equivalents, Marketable Securities
19.98
11.67
12.43
24.23
25.17
17.28
25.58
138
93.31
203
448
407
513
822
734
919
799
  Accounts Receivable
--
--
--
--
--
--
--
--
9.30
--
--
41.16
4.72
26.19
--
14.09
--   Other Current Receivables
19.98
11.67
12.43
24.23
25.17
17.28
25.58
138
103
203
448
448
517
848
734
934
799
Total Receivables
--
--
--
--
--
--
--
--
--
--
--
--
--
--
2.08
0.56
--   Inventories, Raw Materials & Components
--
--
--
--
--
--
--
--
--
--
--
--
--
--
-2.38
-2.93
--   Inventories, Inventories Adjustments
--
--
--
--
--
--
--
--
--
--
--
--
--
--
8.76
11.02
--   Inventories, Finished Goods
--
--
--
--
--
--
--
--
--
--
--
--
--
--
-0.00
--
12.00
  Inventories, Other
--
--
--
--
--
--
--
--
--
--
--
--
--
--
8.46
8.65
12.00
Total Inventories
148
126
60.21
2.37
--
--
0.00
--
-0.00
--
0.00
-0.00
--
0.00
-0.00
0.00
-- Other Current Assets
414
432
265
293
313
452
537
693
976
1,139
2,093
3,106
3,461
4,061
4,920
3,886
4,037
Total Current Assets
--
--
--
--
--
--
--
--
--
--
22.34
179
56.48
19.14
19.90
31.81
30.00
Investments And Advances
8.25
6.72
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--   Buildings And Improvements
25.95
24.39
24.47
24.70
23.48
22.22
21.55
21.06
27.38
33.24
41.83
68.76
81.75
93.41
135
138
--   Machinery, Furniture, Equipment
0.19
0.67
0.30
--
--
--
0.14
0.78
10.88
0.15
7.35
2.31
7.92
33.54
5.79
14.37
--   Construction In Progress
0.00
0.00
6.68
1.70
1.78
1.57
1.41
1.36
1.73
14.55
41.23
94.21
115
135
203
228
271
  Other Gross PPE
34.39
31.79
31.45
26.40
25.26
23.79
23.10
23.20
40.00
47.95
90.40
165
204
262
344
381
271
Gross Property, Plant and Equipment
-22.80
-24.40
-25.80
-21.80
-21.07
-19.60
-18.88
-18.64
-21.72
-23.13
-28.34
-43.64
-56.02
-71.25
-100
-117
--   Accumulated Depreciation
11.59
7.39
5.65
4.60
4.20
4.19
4.22
4.56
18.28
24.82
62.07
122
148
190
244
264
271
Property, Plant and Equipment
--
--
--
--
0.47
10.21
28.22
25.74
20.05
72.00
70.46
55.87
38.67
21.01
15.00
2,076
2,111
Intangible Assets
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
354
355
  Goodwill
2.51
3.71
2.66
2.33
2.47
1.98
1.93
17.90
49.27
60.66
22.49
32.56
44.30
43.18
40.68
134
137
Other Long Term Assets
14.09
11.10
8.31
6.93
7.13
16.38
34.37
48.19
87.59
157
177
389
288
274
319
2,505
2,549
Total Long-Term Assets
428
443
273
300
320
468
572
741
1,064
1,296
2,270
3,495
3,749
4,335
5,239
6,391
6,586
Total Assets
8.63
5.84
--
--
--
--
4.69
3.15
--
--
--
23.97
--
--
--
--
--   Accounts Payable
--
--
--
--
--
--
--
8.72
--
19.61
10.94
--
--
--
8.02
239
229
  Total Tax Payable
--
--
16.95
13.99
16.11
17.22
12.28
11.68
28.44
48.41
126
150
225
247
343
486
507
  Other Current Payables
8.63
5.84
16.95
13.99
16.11
17.22
16.96
23.55
28.44
68.02
137
174
225
247
351
724
736
Accounts Payable & Accrued Expense
--
20.65
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--   Short-Term Debt
1.35
1.09
1.01
0.67
0.39
0.04
0.02
--
--
--
3.90
6.94
9.44
10.65
13.36
12.84
14.00
  Short-Term Capital Lease Obligation
1.35
21.74
1.01
0.67
0.39
0.04
0.02
--
--
--
3.90
6.94
9.44
10.65
13.36
12.84
14.00
Short-Term Debt & Capital Lease Obligation
--
--
151
193
151
89.84
41.41
32.28
24.28
--
--
4.30
3.96
4.75
4.90
3.35
6.00
  Current Deferred Revenue
--
--
151
193
151
89.84
41.41
32.28
24.28
--
--
4.30
3.96
4.75
4.90
3.35
6.00
DeferredTaxAndRevenue
163
209
1.85
1.87
0.16
--
2.31
2.40
--
--
--
22.15
--
-0.00
--
--
-- Other Current Liabilities
173
236
170
210
168
107
60.70
58.23
52.72
68.02
141
207
239
262
369
741
756
Total Current Liabilities
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--   Long-Term Debt
3.45
2.11
1.06
0.34
0.07
0.02
--
--
--
--
23.24
45.78
55.26
75.28
101
131
129
  Long-Term Capital Lease Obligation
3.45
2.11
1.06
0.34
0.07
0.02
--
--
--
--
23.24
45.78
55.26
75.28
101
131
129
Long-Term Debt & Capital Lease Obligation
0.02
0.12
0.02
0.02
0.00
--
--
--
--
--
0.01
0.02
0.02
0.02
0.02
0.03
0.03
Debt-to-Equity
--
--
--
--
--
--
--
--
--
--
--
80.49
74.14
69.09
71.27
396
400
NonCurrent Deferred Liabilities
--
--
12.60
21.54
30.12
28.77
--
--
0.39
0.31
0.15
0.17
1.98
1.58
5.20
4.19
5.00
NonCurrent Deferred Income Tax
1.55
11.61
4.02
0.47
0.27
0.23
0.21
--
0.19
0.15
0.30
0.66
0.00
0.00
-0.00
-0.00
-- Other Long-Term Liabilities
5.00
13.72
17.68
22.34
30.45
29.03
0.21
--
0.58
0.46
23.69
127
131
146
177
531
534
Total Long-Term Liabilities
178
250
188
232
198
136
60.91
58.23
53.30
68.48
164
334
370
408
546
1,272
1,290
Total Liabilities
8.65
8.01
7.84
8.92
9.58
9.30
8.72
8.54
9.86
9.35
9.75
10.91
10.05
9.50
9.80
9.21
10.00
Common Stock
-804
-790
-874
-972
-992
-821
-619
-440
-299
-30.33
319
1,175
1,525
2,131
2,824
3,286
3,537
Retained Earnings
--
--
12.64
14.24
14.29
13.73
13.84
14.56
13.23
14.09
14.69
8.93
12.33
14.11
8.91
68.36
-213
Accumulated other comprehensive income (loss)
1,035
959
938
1,016
1,090
1,130
1,108
1,099
1,287
1,235
1,762
1,966
1,831
1,772
1,850
1,757
1,962
Additional Paid-In Capital
9.99
16.01
0.00
0.00
0.00
0.00
-0.00
-0.00
0.00
0.00
--
-0.00
-0.00
0.00
0.00
0.00
-- Other Stockholders Equity
250
193
84.90
67.92
122
332
511
683
1,011
1,228
2,106
3,160
3,379
3,927
4,693
5,120
5,296
Total Stockholders Equity
250
193
84.90
67.92
122
332
511
683
1,011
1,228
2,106
3,160
3,379
3,927
4,693
5,120
5,296
Total Equity
0.58
0.44
0.31
0.23
0.38
0.71
0.89
0.92
0.95
0.95
0.93
0.90
0.90
0.91
0.90
0.80
0.80
Equity-to-Asset
* All financial numbers are in millions except for per share data, ratios and percentage change.
GuruFocus Manual of Stocks™  |  Jun 30, 2025
Genmab AS (NAS:GMAB)
www.gurufocus.com/stock/NAS:GMAB/summary

Valuation Ratios

Valuation Ratios

Dec09
Dec10
Dec11
Dec12
Dec13
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
Dec23
Dec24
TTM Fiscal Period
N/A
At Loss
At Loss
At Loss
97.43
69.52
72.77
61.16
57.14
44.78
43.19
33.74
58.64
35.23
32.17
12.38
12.25
PE Ratio
N/A
At Loss
At Loss
At Loss
119
69.16
72.05
63.02
46.60
50.49
44.89
30.71
73.23
37.34
29.09
14.40
13.52
PE Ratio without NRI
--
--
--
--
--
293
335
276
46.06
96.94
124
28.43
87.91
52.98
24.88
13.73
11.95
Price-to-Owner-Earnings
--
3.15
3.44
10.37
16.57
10.05
15.62
14.62
10.02
8.23
6.88
8.42
7.69
7.06
4.43
2.59
2.28
PB Ratio
--
3.15
3.44
10.37
16.64
10.37
16.52
15.20
10.22
8.74
7.12
8.57
7.78
7.09
4.45
4.36
3.80
Price-to-Tangible-Book
--
11.34
--
57.42
--
366
316
246
42.03
123
76.99
26.21
87.74
53.43
19.99
13.00
11.31
Price-to-Free-Cash-Flow
--
10.91
--
50.13
--
158
178
222
39.68
64.96
70.54
24.96
77.82
49.10
18.97
12.49
10.64
Price-to-Operating-Cash-Flow
6.39
5.03
4.88
7.33
16.47
24.62
49.02
39.98
26.66
21.80
17.43
15.88
20.60
13.24
8.50
4.51
3.99
PS Ratio
--
--
--
--
--
--
--
--
--
0.75
1.12
0.60
1.56
0.81
0.91
1.24
0.70
PEG Ratio
4.25
2.42
1.77
4.92
14.07
21.37
44.94
36.84
23.93
19.52
15.77
14.21
18.25
11.62
6.76
3.50
3.12
EV-to-Revenue
-32.33
-22.82
-3.23
-24.78
116
57.92
64.50
57.11
49.83
34.74
28.16
23.27
36.76
22.93
18.56
7.77
7.19
EV-to-EBITDA
-15.49
-17.03
-3.00
-21.42
136
60.29
67.21
59.18
53.10
36.63
29.53
24.29
39.07
24.12
19.51
8.12
7.54
EV-to-EBIT
-4.25
5.46
-1.40
38.52
-67.50
317
289
227
37.74
110
69.65
23.45
77.73
46.86
15.90
10.09
8.14
EV-to-FCF
-6.46
-5.87
-33.33
-4.67
0.74
1.66
1.49
1.69
1.88
2.73
3.39
4.12
2.56
4.15
5.13
12.32
13.26
Earnings Yield (Joel Greenblatt) %
--
--
--
-7.33
-1.75
--
--
--
--
20.75
20.78
21.25
21.30
21.40
22.79
16.84
16.27
Forward Rate of Return (Yacktman) %
--
--
--
--
--
--
--
--
15,862
431
173
144
111
83.55
51.28
27.70
23.44
Shiller PE Ratio
--
--
--
--
--
--
--
--
25.68
22.75
24.75
29.30
22.49
17.79
10.22
5.69
4.70
Cyclically Adjusted PB Ratio
--
--
--
--
--
--
--
--
57.41
50.63
52.53
57.46
47.06
35.47
19.98
10.67
8.79
Cyclically Adjusted PS Ratio
--
--
--
--
--
--
--
--
638
468
259
164
135
110
56.54
29.91
24.53
Cyclically Adjusted Price-to-FCF
--
7.59
-26.57
1.56
-1.27
0.28
0.32
0.42
2.39
0.81
1.26
3.81
1.16
1.87
5.00
7.86
8.52
FCF Yield %

Valuation and Quality

Dec09
Dec10
Dec11
Dec12
Dec13
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
Dec23
Dec24
TTM Fiscal Period
--
606
292
704
2,024
3,338
7,977
9,989
10,128
10,106
14,495
26,597
25,998
27,704
20,801
13,261
12,721
Market Cap
--
336
102
439
1,736
2,904
7,466
9,435
9,254
9,170
12,877
23,992
23,119
24,577
16,738
10,460
9,570
Enterprise Value
--
1.35
0.65
1.40
3.91
5.86
13.40
16.58
16.58
16.48
22.33
40.66
39.56
42.38
31.84
20.87
20.63
Month End Stock Price
0.15
0.10
0.01
0.07
0.17
0.52
0.76
0.82
1.34
1.41
2.28
3.55
3.92
4.29
5.56
2.63
3.06
Net Cash per Share
0.52
0.40
0.17
0.12
0.22
0.55
0.80
1.05
1.51
1.75
2.97
4.24
4.70
5.59
6.70
4.11
4.34
Net Current Asset Value
0.18
0.12
0.03
0.10
0.21
0.55
0.79
1.00
1.46
1.66
2.80
4.02
4.50
5.23
6.41
3.72
4.01
Net-Net Working Capital
--
--
--
--
-0.26
0.12
0.65
0.80
2.51
3.05
4.67
10.00
10.68
12.78
17.09
20.84
22.74
Intrinsic Value: Projected FCF
--
--
--
--
--
--
--
--
--
13.91
27.22
59.09
43.67
78.15
89.70
102
113
Median PS Value
--
--
--
--
--
--
--
--
--
9.25
13.49
32.00
10.30
30.10
27.56
16.27
16.53
Peter Lynch Fair Value
--
--
--
--
0.42
1.05
1.84
2.55
3.58
3.70
5.89
11.83
7.90
12.28
13.22
12.53
13.14
Graham Number
--
--
--
-0.33
-0.53
0.30
0.82
1.43
2.79
3.33
5.12
8.16
8.76
10.96
14.46
14.85
17.98
Earnings Power Value (EPV)
0.84
-0.50
-3.24
-2.35
2.83
14.04
78.95
105
114
89.39
54.46
50.35
45.08
43.28
25.45
8.68
7.90
Altman Z-Score
4.00
6.00
3.00
5.00
5.00
6.00
5.00
6.00
6.00
5.00
4.00
6.00
2.00
6.00
4.00
5.00
6.00
Piotroski F-Score
--
74.52
-3.03
-4.57
-1.47
-1.42
-0.78
1.26
-2.65
-1.29
-1.60
-2.23
-2.60
-1.81
-3.08
6.94
8.34
Beneish M-Score
0.01
-0.18
-0.24
-0.72
-0.55
-0.32
-0.00
0.22
0.19
0.28
0.38
0.25
0.14
0.21
0.15
0.44
0.35
Scaled Net Operating Assets
-63.71
6.00
-43.08
-8.37
10.01
41.14
23.91
35.77
2.77
26.42
18.64
3.20
6.86
14.28
-4.95
21.79
17.39
Sloan Ratio %
2.39
1.83
1.55
1.40
1.87
4.22
8.85
11.90
18.52
16.74
14.88
15.00
14.50
15.48
13.34
5.25
5.34
Current Ratio
2.39
1.83
1.55
1.40
1.87
4.22
8.85
11.90
18.52
16.74
14.88
15.00
14.50
15.48
13.32
5.24
5.32
Quick Ratio
1.42
1.25
1.13
1.27
1.72
4.06
8.43
9.53
16.58
13.75
11.70
12.83
12.33
12.25
11.33
3.98
4.27
Cash Ratio
--
--
--
--
20.81
65.40
6,293
4,966
673
No Debt
377
631
227
161
76.01
58.36
59.17
Interest Coverage
--
1.35
1.35
1.42
4.67
6.00
13.94
19.37
23.48
21.68
24.14
40.76
48.72
47.06
43.22
32.77
28.56
Highest Stock Price
--
1.17
0.65
0.65
1.40
3.40
5.78
9.70
16.29
12.12
14.53
17.15
30.92
26.83
27.94
20.02
17.24
Lowest Stock Price
-0.59
-0.01
--
-12.03
-2.88
-10.07
-4.50
-1.21
-1.39
-0.38
-5.86
-0.77
-0.47
0.53
0.06
2.74
2.76
Shares Buyback Ratio %
--
--
--
-9.22
--
-4.88
--
0.17
--
0.22
-4.01
--
0.26
0.47
0.40
4.08
3.94
Buyback Yield %
-13.45
-7.97
-41.13
37.50
26.74
2.53
12.35
52.38
47.60
21.66
69.21
101
-23.50
63.04
17.33
25.22
17.75
YoY Rev. per Sh. Growth
-7.18
70.44
-81.25
18.97
121
115
114
47.83
5.15
27.27
40.11
134
-42.88
74.34
-17.58
72.76
35.95
YoY EPS Growth
84.72
24.24
-200
50.67
178
207
113
41.05
10.07
42.37
68.57
119
-37.83
66.36
-15.61
54.81
23.51
YoY EBITDA Growth
--
--
--
--
--
--
--
--
--
67.25
40.01
50.82
46.95
45.92
32.09
11.63
19.40
5-Year EBITDA Growth Rate
449
449
449
460
510
563
585
599
608
613
630
652
654
654
653
642
637
Shares Outstanding (Basic Average)
449
449
449
503
518
570
595
603
611
613
649
654
657
654
653
635
616
Shares Outstanding (EOP)
--
--
--
--
1.32
0.86
1.07
1.00
0.78
0.54
-0.07
0.59
0.71
1.05
1.00
0.88
0.82
Beta
03/19/10
03/16/11
03/07/12
03/07/13
03/04/14
03/02/15
02/17/16
02/22/17
02/22/18
02/20/19
03/30/20
03/29/21
02/16/22
02/22/23
02/14/24
02/12/25
  Filing Date
03/16/11
03/07/12
03/07/13
03/04/14
03/02/15
02/17/16
02/22/17
02/22/18
03/30/20
03/29/21
02/16/22
02/22/23
02/14/24
02/12/25
02/12/25
02/12/25
  Restated Filing Date
02/20/19
02/19/20
02/23/21
02/16/22
02/14/24
02/12/25
  Earnings Release Date
565
189
179
180
180
180
180
180
180
180
548
781
1,212
1,660
2,204
2,682
2,638
Number of Employees
* All financial numbers are in millions except for per share data, ratios and percentage change.
GuruFocus Manual of Stocks™  |  Jun 30, 2025
Genmab AS (NAS:GMAB)
www.gurufocus.com/stock/NAS:GMAB/summary

Business & Geographic Segmentation

Business Segments

Dec09
Dec10
Dec11
Dec12
Dec13
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
Dec23
Dec24
TTM Fiscal Period
--
--
--
--
--
--
--
--
--
--
--
--
924
1,434
1,673
1,942
601
DARZALEX
--
--
--
--
--
--
--
--
--
--
--
--
35.78
112
222
310
92.44
Kesimpta
--
--
--
--
--
--
--
--
--
--
--
--
--
0.86
62.51
243
72.75
Net product sales
--
--
--
--
--
--
--
--
--
--
--
--
145
254
175
140
1.74
Milestone revenue
--
--
--
--
--
--
--
--
--
--
--
--
80.84
118
128
139
44.83
Reimbursement revenue
--
--
--
--
--
--
--
--
--
--
--
--
90.28
115
105
103
26.74
TEPEZZA
--
--
--
--
--
--
--
--
--
--
--
--
2.13
5.90
35.93
65.71
21.28
Other
--
--
--
--
--
--
--
--
--
--
--
--
3.05
47.78
45.58
60.41
18.54
Collaboration revenue
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.28
-- License revenue
--
--
--
--
--
--
--
--
--
--
804
1,671
1,291
2,101
--
--
-- Single segment

Geographic Segments

Dec09
Dec10
Dec11
Dec12
Dec13
Dec14
Dec15
Dec16
Dec17
Dec18
Dec19
Dec20
Dec21
Dec22
Dec23
Dec24
TTM Fiscal Period
--
--
--
--
--
--
--
257
381
463
804
1,671
1,291
2,101
2,383
2,760
-- Denmark
--
--
--
--
--
--
--
--
--
--
--
--
--
--
56.42
126
-- United States
--
--
--
--
--
--
--
--
--
--
--
--
--
--
6.09
117
-- Japan
* All financial numbers are in millions except for per share data, ratios and percentage change.
GuruFocus Manual of Stocks™  |  Jun 30, 2025
Genmab AS (NAS:GMAB)
www.gurufocus.com/stock/NAS:GMAB/summary

Explanation

1. Predictability Rank

GuruFocus Predictability Rank is a proprietary ranking of the consistency of a business. We rank the predictability of companies based on the consistency of their revenue per share and EBITDA (earnings before interest, tax, depreciation and amortization) per share over the past 10 fiscal years. Our study found that there is a strong correlation between the stock performance and the predictability of a business. Over the long term, companies with higher predictability also have better stock performance.

The rank is from 1-star to 5-star, with 5-star as the best.

2. Financial Strength

GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:

  1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
  2. Debt to revenue ratio. The lower, the better.
  3. Altman Z-Score.

The rank is from 1 to 10, with 10 as the highest.

A Financial Strength rank of 8 or above indicates good financial strength; between 4-7 indicates fair financial strength; 3 or below means poor financial strength.

3. Profitability Rank

GuruFocus Profitability Rank indicates how profitable a company is and how likely it is that the company's business will stay that way. It is based on these factors:

  1. Operating Margin %.
  2. Piotroski F-Score.
  3. Trend of the Operating Margin percentage (five-year average). A company with an uptrend in profit margin will have a higher rank.
  4. Consistency of the profitability.
  5. Predictability Rank.

The rank is from 1 to 10, with 10 as the highest.

A Profitability Rank of 8 or above indicates good profitability; between 4-7 indicates fair profitability; 3 or below means poor profitability.

4. Peter Lynch Chart

In Peter Lynch's excellent book, "One Up on Wall Street," he used many charts to illustrate the valuation of stocks. “A quick way to tell if a stock is overpriced is to compare the price line to the earnings line. If you bought familiar growth companies – such as Shoney’s, The Limited, or Marriott – when the stock price fell well below the earnings line, and sold them when the stock price rose dramatically above it, the chances are you’d do pretty well.”

The original Peter Lynch Chart does have limitations due to the right side price scale is pre-set at 15 times the earnings scale on the left side. When the stock price and earnings line coincide, the price-to-earnings ratio is always 15 times. Instead of using the fixed PE Ratio of 15, our approach is using 15-year historical median PE without NRI Ratio for each stock.

The Peter Lynch Chart with earnings line at median PE without NRI ratio works well for the companies with steady growth and earnings trends, or the stalwarts, as coined by Lynch. These companies tend to be found in sectors such as consumer staples, healthcare, and utilities, where the consumption of the product or service is relatively independent of economic conditions. It does not work well with the sectors that are cyclical: industrials, chemicals, durable goods, and so forth.

5. GF Value

Based on the relationship between the current stock price and the GF Value, GuruFocus provides the following 6 evaluations:

  1. Possible Value Trap, Think Twice
  2. Significantly Overvalued
  3. Modestly Overvalued
  4. Fairly Valued
  5. Modestly Undervalued
  6. Significantly Undervalued
There is only a sufficient margin of safety when the stock is undervalued.

Disclaimer

GuruFocus.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The gurus may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.